SCHEMBL28051

SCHEMBL28051

O=[C]OCCS(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 1/20 0.47
HSD11B1 P28845 5/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 2/20 0.40
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
MEN1 O00255 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5664985 0.93 HTR6 (0.47) PSIP1HSD11B1KEAP1NFE2L2MAPT
SCHEMBL64436 0.81 ALDH1A1 (0.63) MAPTALDH1A1KMT2AMEN1CYP3A4
SCHEMBL619004 0.81 LMNA (0.41) ALDH1A1KMT2AMMP8MMP13MEN1
SCHEMBL2587720 0.81 ALDH1A1 (0.44) MAPTALDH1A1KMT2AMMP1MMP8
SCHEMBL5859628 0.80 PSIP1 (0.56) PSIP1HSD11B1KEAP1NFE2L2MAPT
SCHEMBL9425545 0.80 ALDH1A1 (0.50) MAPTALDH1A1L3MBTL1HDAC3HDAC4
SCHEMBL28865930 0.79 ALDH1A1 (0.38) KEAP1NFE2L2ALDH1A1KMT2AMMP1
SCHEMBL28932041 0.79 ALDH1A1 (0.38) MAPTALDH1A1KMT2AMMP1MMP3
SCHEMBL28166558 0.79 ALDH1A1 (0.59) MAPTALDH1A1KMT2AMEN1CYP3A4
SCHEMBL82994 0.78 CA1 (0.44) HSD11B1MAPTALDH1A1MMP1MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 986 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2921499-B1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS TAKEDA PHARMACEUTICALS CO (JP) 2020-01-22 EP claimed
US-20160075680-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES FUNDACION IMDEA NANOCIENCIA (ES) 2016-03-17 US claimed
EP-2992002-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES Fundación Imdea Nanociencia (ES) 2016-03-09 EP claimed
WO-2014177533-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES FUNDACIÓN IMDEA NANOCIENCIA (ES) 2014-11-06 WO claimed
EP-2799443-A1 Modified solid support for the synthesis of oligonucleotides Fundación Imdea Nanociencia (ES) 2014-11-05 EP claimed
EP-1514542-B1 Medicinal composition comprising Tacrine or Donepezil for improving brain function. TOYAMA CHEMICAL CO LTD (JP) 2012-02-22 EP claimed
CN-100579957-C Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO LTD 2010-01-13 CN claimed
CN-100434079-C Pyrazine nucleotide/pyrazine nucleoside analogue and medical application thereof FUJIYAMA CHEMICAL IND CO LTD (JP) 2008-11-19 CN claimed
EP-0840741-B1 PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION PERSEPTIVE BIOSYSTEMS INC (US) 2004-04-28 EP claimed
JP-2001518054-A 2001-10-09 JP claimed
EP-0840741-A1 PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION PERSEPTIVE BIOSYSTEMS, INC. (US) 1998-05-13 EP claimed
WO-1996040709-A1 PNA-DNA CHIMERAS AND PNA SYNTHONS FOR THEIR PREPARATION PERSEPTIVE BIOSYSTEMS, INC. (US) 1996-12-19 WO claimed
EP-0641207-A4 ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF. SCRIPPS RESEARCH INST (US) 1996-08-14 EP claimed
US-5527805-A DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS THE SCRIPPS RESEARCH INSTITUTE (US) 1996-06-18 US claimed
EP-0641207-A1 ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 1995-03-08 EP claimed
WO-1993023046-A1 ENANTIOMERIC CYNEMICIN ANALOGS, PREPARATION AND USE THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 1993-11-25 WO claimed
EP-0074763-B1 A COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL KONICA CORPORATION (JP) 1986-03-05 EP claimed
CN-118284608-A Compounds as BCL-2 inhibitors 重庆复创医药研究有限公司 2024-07-02 CN disclosed
US-4297437-A WHEREIN THE DEVELOPER IS REPLENISHED KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-10-27 US disclosed
EP-0029722-A1 A processing method for silver halide colour photographic material KONICA CORPORATION (JP) 1981-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075680-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES POLR2H, POLRMT, POLR2E PSIP1 403/4885HSD11B1 4415/4885KEAP1 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.